• 1.

    Macdougall IC, et al.. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447458.

  • 2.

    Rostoker G, Vaziri ND, Fishbane S. Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. Drugs 2016; 76:741757.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47:S11S145.

    • Search Google Scholar
    • Export Citation
  • 4.

    Charytan DM, et al.. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015; 26:12381247.

  • 5.

    Anker SD, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:24362448.

  • 6.

    Anker SD, et al.. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018; 20:125133.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Coyne, DW. Iron overload in dialysis patients: rust or bust? Kidney Int Rep 2017; 2:995997.

  • 8.

    Kapoian T, et al.. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19:372379.

  • 9.

    Coyne DW. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18:975984.

    • Crossref
    • Search Google Scholar
    • Export Citation

Clinical Place of Iron in the 21st Century

  • 1 Daniel W. Coyne, MD, is professor of medicine, division of nephrology at Washington University, St. Louis, MO.
Restricted access
Save